PMID- 28131071
OWN - NLM
STAT- MEDLINE
DCOM- 20170419
LR  - 20221207
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 125
DP  - 2017 Mar
TI  - Early drug use of dapagliflozin prescribed by general practitioners and 
      diabetologists in Germany.
PG  - 29-38
LID - S0168-8227(16)31538-8 [pii]
LID - 10.1016/j.diabres.2016.10.025 [doi]
AB  - OBJECTIVES: Dapagliflozin is an inhibitor of the human sodium-glucose 
      co-transporter 2 (SGLT2) that has been shown to improve glycaemic control in 
      patients with type 2 diabetes mellitus (T2DM). This study aimed to evaluate the 
      characteristics and treatment patterns of dapagliflozin users in comparison to 
      users of other anti-diabetic (AD) treatments in Germany. METHODS: Data from 
      patients with T2DM initiating at least one prescription for dapagliflozin or 
      other AD therapy between November 2012 and April 2014 were collected from the IMS 
      German Disease Analyzer database. RESULTS: The use of dapagliflozin combination 
      therapy (n=1034; 74%) was more common than monotherapy (n=371; 26%). In 
      comparison with other AD therapy users, a higher percentage of dapagliflozin 
      users were ⩽64years of age (62.3% vs. 36.4%), and a higher proportion were male 
      (59.1% vs. 53.6%). The average duration of diabetes was comparable between 
      dapagliflozin patients and other AD therapy users (5.7yearsvs. 5.5years), however 
      higher levels of HbA1c were found in dapagliflozin users (8.2% (66mmol/mol) vs. 
      7.5% (58mmol/mol). For the vast majority (71.5% of 10mg dapagliflozin users and 
      88.9% of 5mg users), dapagliflozin was prescribed in combination with other AD 
      therapy. CONCLUSIONS: Patients starting on dapagliflozin differed in several 
      demographic and health-related respects to patients starting another AD therapy 
      during the same period. Dapagliflozin was predominantly used as a component of 
      combination therapy, adding on to existing therapy. After initiation, switching 
      to other AD treatments or adding to therapy was comparatively rare during the 
      first year.
CI  - Copyright (c) 2016 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Hankins, Matthew
AU  - Hankins M
AD  - Real World Evidence Solutions, QuintilesIMS, London, UK; Institute of 
      Pharmaceutical Science, King's College, London. Electronic address: 
      MHankins@uk.imshealth.com.
FAU - Tsai, Katherine
AU  - Tsai K
AD  - Medical Evidence & Observational Research, Global Medical Affairs, AstraZeneca, 
      Gaithersburg, USA.
FAU - Kim, Joseph
AU  - Kim J
AD  - Real World Evidence Solutions, QuintilesIMS, London, UK; Faculty of Epidemiology 
      and Population Health, London School of Hygiene and Tropical Medicine, London.
FAU - Hammar, Niklas
AU  - Hammar N
AD  - Medical Evidence & Observational Research, Global Medical Affairs, AstraZeneca, 
      Molndal, Sweden; Department of Epidemiology, Institute of Environmental Medicine, 
      Karolinska Institutet, Stockholm, Sweden. Electronic address: 
      Niklas.Hammar@astrazeneca.com.
LA  - eng
PT  - Journal Article
DEP - 20161109
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 1ULL0QJ8UC (dapagliflozin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Benzhydryl Compounds/administration & dosage/*therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - General Practitioners
MH  - Germany
MH  - Glucosides/administration & dosage/*therapeutic use
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Anti-diabetic
OT  - Dapagliflozin
OT  - Diabetes
EDAT- 2017/01/29 06:00
MHDA- 2017/04/20 06:00
CRDT- 2017/01/29 06:00
PHST- 2016/06/23 00:00 [received]
PHST- 2016/10/12 00:00 [revised]
PHST- 2016/10/30 00:00 [accepted]
PHST- 2017/01/29 06:00 [pubmed]
PHST- 2017/04/20 06:00 [medline]
PHST- 2017/01/29 06:00 [entrez]
AID - S0168-8227(16)31538-8 [pii]
AID - 10.1016/j.diabres.2016.10.025 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2017 Mar;125:29-38. doi: 10.1016/j.diabres.2016.10.025. 
      Epub 2016 Nov 9.